PsychedelicMentalHealthM to Psychedelic and Plant Medicine Therapists, Practitioners, ProvidersEnglish • 10 months ago

MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder

2

MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder

PsychedelicMentalHealthM to Psychedelic and Plant Medicine Therapists, Practitioners, ProvidersEnglish • 10 months ago

-A single oral administration of MM120 100 µg met its key secondary endpoint and maintained a clinically and statistically significant…...

You must log in or register to comment.

Chat